TABLE 1A.
Demographics of Acute and Ongoing Patients
| Case | Sex | Age, Decade | Symptom Onset, Days | COVID‐19 Severity a | Neuropsychiatric Symptoms | MMST b | MOCA b | NPT b |
|---|---|---|---|---|---|---|---|---|
| Acute COVID‐19 | ||||||||
| Case 1 | M | 81–90 | 0 | Mild | Headache, gait disturbance | |||
| Case 2 | M | 61–70 | 6 | Severe | Flaccid paraparesis, delirium, inflammatory neuropathy | |||
| Case 3 | M | 61–70 | 13 | Critical | Delirium | |||
| Case 4 | F | 81–90 | 9 | Critical | Delirium, myoclonus, transient hemiparesis | |||
| Case 5 | F | 31–40 | 21 | Mild | Cognitive deficits, headache, dizziness, fatigue | 27 | ||
| Case 6 | F | 71–80 | 21 | Critical | Delirium, aphasia, impaired consciousness | |||
| Case 7 | F | 71–80 | 20 | Severe | Cognitive deficits, delirium, change in personality | |||
| Case 8 | M | 51–60 | 28 | Critical | Delirium, generalized seizure, critical illness weakness | |||
| Case 9 | M | 61–70 | 13 | Critical | Gaze saccades, ataxia, delirium | |||
| Case 10 | F | 61–70 | 1 | Critical | Delirium | |||
| Case 11 | M | 51–60 | 29 | Critical | PRES, intracranial hemorrhage | |||
| Case 12 | F | 81–90 | 30 | Critical | Paresis left arm | |||
| Median (range) | 63 (56–86) | 16.5 (0–30) | ||||||
| Ongoing COVID‐19 | ||||||||
| Case 13 | M | 21–30 | 43 | Critical | Cognitive deficits, delirium, delayed polyneuropathy | 29 | ||
| Case 14 | F | 51–60 | 55 | Mild | Myelitis with paraparesis | |||
| Case 15 | F | 63 | Mild | Myelitis with paraparesis | ||||
| Case 16 | F | 41–50 | 43 | Mild | Dizziness, limb weakness | |||
| Case 17 | M | 71–80 | 39 | Severe | Cognitive deficits, delirium, ocular motility dysfunction | |||
| Case 18 | M | 31–40 | 53 | Mild | Cognitive deficits, fatigue, depression | 30 | ||
| Case 19 | F | 71–80 | 66 | Mild | Transient ischemic attack, dizziness | |||
| Case 20 | M | 71–80 | 37 | Severe | Guillain–Barré syndrome | |||
| Median (range) | 48 (24–77) | 48.0 (37–66) | ||||||
COVID‐19 severity: mild: any of the various signs and symptoms of COVID‐19 but no shortness of breath, dyspnea, or abnormal chest imaging; moderate: evidence of lower respiratory disease during clinical assessment or imaging and an oxygen saturation (SpO2) ≥ 94% on room air at sea level; severe: SpO2 < 94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen < 300mmHg, respiratory frequency > 30 breaths/min, or lung infiltrates >50%; critical: respiratory failure, septic shock, and/or multiple organ dysfunction (https://www.covid19treatmentguidelines.nih.gov/, accessed October 3, 2021).
Blank: testing not performed.
F = female; M = male; MMST = Mini‐Mental Status Test; MOCA = Montreal Cognitive Assessment, considered pathological for values < 26; NPT = neuropsychological testing battery covering several cognitive domains including learning and memory, attention, executive functioning, language, and visuoconstruction; PRES: posterior reversible encephalopathy syndrome.